Project: Every Child for Younger Patients With Cancer

What this study is about

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Who can join (things the study team will check)

✅ You may be able to join if…

• Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem
• Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority
• Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
  • All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)
  • All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
  • All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant
  • The following other benign/borderline conditions:
  • Mesoblastic nephroma
  • Teratomas (mature and immature types)
  • Myeloproliferative diseases including transient myeloproliferative disease
  • Langerhans cell histiocytosis
  • Lymphoproliferative diseases
  • Desmoid tumors
  • Gonadal stromal cell tumors
  • Neuroendocrine tumors including pheochromocytoma
  • Melanocytic tumors, except clearly benign nevi
  • Ganglioneuromas
• Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit
• All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission
  • If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1

Where this trial is running

• Children's Hospital of Alabama, Birmingham, Alabama, United States
• USA Health Strada Patient Care Center, Mobile, Alabama, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Kingman Regional Medical Center, Kingman, Arizona, United States
• Banner Children's at Desert, Mesa, Arizona, United States
• Phoenix Childrens Hospital, Phoenix, Arizona, United States
• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• Arkansas Children's Hospital, Little Rock, Arkansas, United States
• Kaiser Permanente Downey Medical Center, Downey, California, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Loma Linda University Medical Center, Loma Linda, California, United States
• Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States

+ 266 more sites.